The FDA has accepted for filing and review, and has granted priority review status for a supplemental Biologics License Application (sBLA) for use of Zevalin as consolidation therapy in patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy and expects a decision regarding the sBLA in early April, 2009.
What does SBLA stand for?
SBLA stands for Supplemental Biologics License Application
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of SBLA
We have 5 other meanings of SBLA in our Acronym Attic
- Symbol Technologies, Inc. (NYSE symbol)
- Space-Based Laser Integrated Flight Experiment
- Sound Blaster Live 5
- Sealed Bipolar Lead Acid (battery)
- Self-Bounding Learning Algorithm
- Shannon Bray Landscape Architects (New Zealand)
- Small Business Loans Act (Canada)
- Small Business Loans Association (Saskatchewan, Canada)
- Smash Bros Los Angeles (dance and music group; California)
- State Boating Law Administrator
- Society of Biblical Literature Academia Biblica
- Ship-Board Laser Acquisition System (US Navy)
- Single Precision Basic Linear Algebra Subprogram(s)
- Surveillance Bronchoscopic Lung Biopsy
- Satisfactory but Limited by Lack of Endocervical Component
- S-Band Linear Collider
- SB Latex Council
- School Board of Levy County (Florida)
- School Building Level Committee
- Small Business Lending Companies
Samples in periodicals archive:
Foodand Drug Administration (FDA) has approved an efficacy supplemental biologics license application (sBLA) for ONTAK' (denileukin diftitox) solution for intravenous injection for the treatment of patients with persistent or recurrent cutaneous T-celllymphoma (CTCL) whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+).
In an announcement dated October 4, 2005, Abbott Laboratories announced it has simultaneously submitted a supplemental Biologics License Application with the US Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA as a treatment for ankylosing spondylitis, an inflammatory disease of the spine and spinal joints.